BiotechTube

ICL670

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major

Conditions

Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major

Trial Timeline

Sep 1, 2013 → Oct 1, 2015

NCT ID
NCT01610297

About ICL670

ICL670 is a approved stage product being developed by Novartis for Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major. The current trial status is completed. This product is registered under clinical trial identifier NCT01610297. Target conditions include Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major.

What happened to similar drugs?

4 of 12 similar drugs in Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major were approved

Approved (4) Terminated (0) Active (8)
🔄DeferasiroxNovartisPhase 3
✅DeferasiroxNovartisApproved
✅DesferasiroxNovartisApproved
🔄DeferasiroxNovartisPhase 3
✅deferasiroxNovartisApproved
🔄DeferasiroxNovartisPhase 3
✅DeferasiroxNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01610297ApprovedCompleted
NCT01090323Phase 2Completed
NCT01044186Phase 2Completed

Competing Products

20 competing products in Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major

See all competitors
ProductCompanyStageHype Score
KER-047Keros TherapeuticsPhase 2
17
H. pylori treatmentEisaiPhase 2/3
38
DeferasiroxNovartisPhase 3
40
CSJ137 + PlaceboNovartisPhase 1
29
Deferasirox and DeferoxamineNovartisPhase 2
35
DeferasiroxNovartisPhase 2
35
ICL670NovartisPhase 2
35
DeferasiroxNovartisApproved
43
Deferasirox + DeferasiroxNovartisPhase 2/3
38
DesferasiroxNovartisApproved
43
DeferasiroxNovartisPhase 2
35
DeferasiroxNovartisPhase 3
40
Deferasirox dispersible tablet + Defearisox film-coated tabletNovartisPhase 2
35
deferasiroxNovartisApproved
43
Deferasirox (ICL670)NovartisPhase 1/2
32
DeferasiroxNovartisPhase 3
40
Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + DeferoxamineNovartisPhase 2
35
DeferasiroxNovartisApproved
43
Z-213 + Saccharated Ferric OxideZeria PharmaceuticalPhase 3
40
Z-213Zeria PharmaceuticalPhase 3
40